Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer

Elboğa, Umut; Şahin, Ertan; Kuş, Tülay; Cayirli, Yusuf Burak; Aktaş, Gökmen; Uzun, Evren; Çınkır, Havva Yeşil; Teker, Fatih; Sever, Özlem Nuray; Aytekin, Alper; Yılmaz, Latif; Aytekin, Aydın; Cimen, Ufuk; Mumcu, Vuslat; Kılbaş, Benan; Çelen, Y. Zeki

doi:10.1007/s12149-021-01672-x

Cited by 53 publications

(45 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elboga et al [53] FAPI > FDG FAPI > FDG The sensitivity and specificity of FAPI in detecting primary breast lesions were higher than FDG. The SUV max values of primary tumors and metastases were significantly higher on FAPI imaging than FDG imaging.…”

Section: Development Of Fibroblast Activating Protein Inhibitor Imagi...mentioning

confidence: 94%

See 1 more Smart Citation

Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer

Hua

Shen

et al. 2022

Nuclear Medicine Communications

View full text Add to dashboard Cite

Fibroblast activation protein (FAP) is a type II transmembrane protein, which is over-expressed in cancer-associated fibroblasts (CAFs). CAFs are tumor stromal cells that constitute a major component of cancer volume and are reportedly related to tumorigenesis, angiogenesis, metastasis, promotion of drug resistance and induction of tumor immunity. FAP is widely acknowledged as the signature protein of CAFs. At present, FAP inhibitors (FAPI) have achieved ideal results in tumor PET/computed tomography (CT) imaging. Theoretically, FAP-targeted drugs can inhibit tumor progression. Nonetheless, no satisfactory therapeutic effect has been observed so far, which has impeded their implementation in clinical practice. In this review, we describe the characteristics of FAP and its role in the occurrence and development of cancer. We also highlight the potential value of targeting FAP to improve current diagnostic and therapeutic approaches.

show abstract

Section: Development Of Fibroblast Activating Protein Inhibitor Imagi...mentioning

confidence: 94%

“…He was not contraindicated for anthracycline, and FAPI-PET/CT demonstrated that he had a positive tumor phenotype. Cumulative use of 20GBq~1 53 Sm and 8GBq~9 0 Y-FAPI-46 ( 153 Sm does not have a high enough specific activity) was well tolerated for three cycles, and the disease was stable for 8 months.…”

Section: Radioligand Therapymentioning

confidence: 99%

Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer

Hua

Shen

et al. 2022

Nuclear Medicine Communications

View full text Add to dashboard Cite

show abstract

“…The first reports showed higher diagnostic accuracy for FAPi-PET (sensitivity 100%, specificity 96%) compared to FDG-PET (sensitivity 78%; specificity 100%) in detecting primary tumor, lymph nodes, and distant metastasis. The main advantage was related to the more favorable biodistribution (no liver or brain physiological uptake), together with the ability to detect small lesions, even smaller than 5 mm [25,26]. These promising results have been confirmed in further studies with PET/MRI, that combine the added value of whole-body scanning and accurate morphologic imaging together with functional imaging of the TME [24].…”

Section: Cancer Associated Fibroblast Targeted Positron Emission Tomo...mentioning

confidence: 97%

Imaging for illuminating actionable pathways in breast cancer

Gilardi

Farulla

Ceci

2022

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of reviewNuclear medicine has the potential to explore and illuminate several pathways in breast cancer (BC) offering different radiopharmaceuticals for positron emission tomography (PET) designed to target specific tumor characteristics. The aim of this critical review is to give an overview about emerging opportunities in PET imaging, underlining the future potential contribution in the management of BC patients.Recent findingsBeside 2-deoxy-2-[18F]-fluoro-d-glucose (FDG), new generation tracers for PET imaging have been recently proposed to investigate specific characteristics in breast cancer, both targeting tumor cells and the tumor micro-environment (TME).SummaryFDG-PET is a procedure that received extensive clinical validation. However, its role in BC is still suboptimal due to the low-FDG avidity of specific tumor subtypes. Human epidermal growth receptor-2 and integrin targeted PET radiotracers might provide useful information selecting patients more likely to respond to target therapy. FluoroEstradiol (FES) is a FDA-approved PET radiotracer targeting the estrogen receptor (ER), useful to investigate metastatic ER+ patients, to assess in vivo ER heterogeneity and to evaluate hormonal therapy efficacy. Inhibitors of the fibroblast activation protein (FAPi) targeting the cancer-associated fibroblast can explore the TME with PET imaging. FAPi is also proposed a theranostic agent for radio-ligand therapy.

show abstract

Section: Fibroblast Activation Protein-α Targeted Radiotracersmentioning

confidence: 99%

“…In 2021, two different studies ( 198 , 199 ) compared [ 68 Ga]Ga-FAPi PET/CT and [ 18 F]F-FDG PET/CT in patients with BC. Elboga et al ( 198 ) aimed to detect additional lesions in BC patients that may affect further chemotherapy options in 48 patients. The study demonstrated more lesions in all categorized regions in [ 68 Ga]Ga-FAPi PET/CT with higher uptake compared to [ 18 F]F-FDG PET/CT.…”

Section: Fibroblast Activation Protein-α Targeted Radiotracersmentioning

confidence: 99%

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Balma¹,

Liberini

Racca

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.

show abstract

Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer

Cited by 53 publications

References 53 publications

Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer

Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer

Imaging for illuminating actionable pathways in breast cancer

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Contact Info

Product

Resources

About